Loading...
DMKP.Q logo

DMK Pharmaceuticals CorporationOTCPK:DMKP.Q Aktienübersicht

Marktkapitalisierung US$10.0
Aktienkurs
US$0.000001
Mein Marktwert
n/v
1Y-100.0%
7D0%
1D
Wert des Portfolios
​
Siehe

DMK Pharmaceuticals Corporation

OTCPK:DMKP.Q Lagerbericht

Marktkapitalisierung: US$10.0

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

DMK Pharmaceuticals (DMKP.Q) Aktienübersicht

DMK Pharmaceuticals Corporation, ein Neurobiotechnologie-Unternehmen in der klinischen Phase, entwickelt und vermarktet Produkte in den therapeutischen Bereichen Allergie, Opioidüberdosierung, Atemwegs- und Entzündungskrankheiten. Mehr Details

DMKP.Q grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung2/6
Künftiges Wachstum0/6
Vergangene Leistung0/6
Finanzielle Gesundheit1/6
Dividenden0/6

Belohnungen

Der Umsatz stieg im vergangenen Jahr um 150.3%

Risikoanalyse

Negatives Eigenkapital

Hat keine nennenswerte Marktkapitalisierung ($10)

Sehr volatiler Aktienkurs in den letzten 3 Monaten im Vergleich zum US -Markt

Die letzten Finanzberichte sind mehr als ein Jahr alt

+ 1 mehr Risiko

DMKP.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

DMK Pharmaceuticals Corporation Wettbewerber

Preisentwicklung & Leistung

Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für DMK Pharmaceuticals
Historische Aktienkurse
Aktueller AktienkursUS$0.000001
52-Wochen-HochUS$1.04
52-Wochen-TiefUS$0.000001
Beta1.35
1 Monat Veränderung-99.00%
3 Monate Veränderung0%
1 Jahr Veränderung-100.00%
3 Jahre Veränderung-100.00%
5 Jahre Veränderung-100.00%
Veränderung seit IPO-100.00%

Aktuelle Nachrichten und Updates

Recent updates

Seeking Alpha • Sep 30

Adamis Pharmaceuticals: Managing A Position In A Company Diagnosed With Chronic Failure

Summary Adamis Pharmaceuticals recently provided an update on Tempol’s Phase II/III COVID-19 trial, which revealed the interim did not demonstrate statistical significance of its primary endpoint. The DSMB has recommended the company halt the trial. The company believes vaccination and the Omicron variant might have influenced the outcomes. Adamis has a long track record of fumbles and failures. I am finally ready to put ADMP on my “Wall of Shame” and ultimately mothball the position. If you have followed my coverage of Adamis Pharmaceuticals (ADMP), you would know that I have a classic "Love/Hate Relationship" with the company and its ticker. On one hand, the company has a portfolio of approved products that are in huge markets. In addition, ADMP has offered countless trading opportunities over the years that have allowed me to generate substantial profit. On the other hand, Adamis has fumbled almost every prospect and has obliterated shareholder value over the years. Recently, Adamis has added TEMPOL to its list of failures after the company announced that it failed to hit its primary endpoint in its Phase II/III trial for COVID-19. This was a major blow to the "Turnaround Bull Thesis" and crushed the share price to all-time lows. Now, I am left deciding whether to actively manage the position in hopes ZIMHI is able to deliver, or just set some sell orders and mothball the ticker. I intend to recap the company's previous blunders and how they impacted the company's long-term outlook. In addition, I will review the TEMPOL update and will provide my views. Finally, I will determine if there is any hope for ADMP and will discuss how I will manage the position going forward. A History of Failure I have been a longstanding investor in Adamis Pharmaceuticals, and during this time I have watched the company establish a track record of failure. When I first got involved with the ticker the company had inhaler product candidates (APC-1000, APC-4000), which were based on the DPI technology from 3M (MMM) that the company acquired the rights back in 2013. The last update that I could remember was in a company press release in 2019, which announced that they had initiated their phase III efficacy studies for APC-100O and APC-4000 and had moved on to the tape portion of the drug/device combination. Sadly, that was really the last word on those programs and they were slowly phased out of the pipeline. It is safe to say that those programs were a disappointment. Adamis had another pipeline flop with their sublingual tadalafil product (APC-8000). The FDA sent Adamis a Refusal to File "RTF" letter regarding their NDA for APC-8000. The FDA determined the NDA was not satisfactory and would necessitate supplementary data to consider approval. Consequently, the company simply gave up on the project to conserve cash. Another disappointment came from their US Compounding subsidiary, which Adamis acquired back in 2016. At that time, the expectation was that US Compounding would be pulling in "$50 million per year with 24 months after closing." However, the subsidiary battled to clear a profit regardless of the company's best efforts. What is more, the company also had some legal issues regarding US Compounding, so they decided to offload the subsidiary for around $10M-20M. At that time, it was nice to hear that $10M-20M would make it into the bank, but ultimately the company most likely lost money on the project over the years. The company's once flagship product, Symjepi, was expected to be a leading competitor against EpiPen and other epinephrine injectors. However, Symjepi took multiple attempts to get through the FDA; the company had a legal dispute with Belcher Pharmaceuticals over the epinephrine formulation; it took over a year to find a commercial partner, and another year for a full-scale commercial launch by Novartis' (NVS) Sandoz division. However, Sandoz was not willing to commit to a traditional marketing campaign or hire a salesforce to focus on allergist offices. As a result, Symjepi sales were far lower than expected, so both companies decided to break the partnership. Adamis was eventually able to find another partner, US WorldMeds, who is taking on the commercial efforts for Symjepi and Zimhi. Unfortunately, Symjepi's relaunch is not going as planned with Adamis having to perform a recall due to a manufacturing defect in the needles. What is more, Symjepi's window of opportunity is starting to close as competition is on the horizon. Aquestive Therapeutics (AQST) just announced that their oral film epinephrine candidate, AQST-109, was able to produce a median Tmax of 12 minutes, which was faster than EpiPen's Tmax of 22.5 minutes. Even if Symjepi is able to relaunch with some support from US WorldMeds, it is only a matter of time before next-gen epinephrine products claim the market. I believe it is safe to say Symjepi has been a huge disappointment. Tempol Failure Recently, Adamis announced that the "third planned interim analysis of the Phase II/III clinical trial examining the effects of Tempol in high-risk subjects with early COVID-19 infection did not achieve its primary endpoint, as measured by comparing the rate of sustained clinical resolution of symptoms of COVID-19 at day 14 of Tempol versus placebo. The independent Data Safety Monitoring Board "DSMB" recommended that the study be halted early due to lack of efficacy." The company has halted the trial and is going to "evaluate the unblinded data from the trial to determine the next developmental steps for Tempol." Obviously, this is a major blow to the turnaround thesis and was a major disappointment considering some of the preclinical work showing Tempol's potential to be a game changer. However, the company did point out that Tempol's preclinical work was based on severe illness and not early COVID-19 infection. What is more, the company believes the COVID-19 environment has changed dramatically in terms of vaccinations, variants, and hospitalization rates, which could have had an impact on the results. Adamis believes there could still be some use for Tempol in severe illness or immunocompromised COVID-19 patients. My Views on Tempol's Failure and Future Admittedly, I was extremely disappointed about Tempol's failure considering its preclinical performance. Indeed, the trial was to examine the effects of Tempol in high-risk subjects with early COVID-19 infection, whereas the preclinical work pointed to severe COVID, which would probably require hospitalization. So perhaps it was just the wrong trial structure to show if Tempol can work in COVID? One must admit that the pandemic is not what it used to be… more people are vaccinated and/or have natural immunity from already having COVID. In addition, the predominant Omicron variant is not as virulent as the native strain or the delta variant. As far as I know… a person in Tempol's trial could be vaccinated and/or already been infected with COVID. So, a less deadly variant and bolstered immune system against COVID probably would have benefited the placebo group. So, it is possible Tempol was not able to show any benefit because the patients were probably unlikely to be hospitalized regardless of Tempol. So is Tempol another failure for Adamis? Well… yes, in terms of the company finding a way to expedite the trial initiation and set up several trial designs for multiple patient populations and disease states. Indeed, Adamis is a small-cap pharmaceutical company that doesn't have the influence or money to pull that off, so we can't blame them for picking one and running with it. One could argue that the company should have gone with the severe COVID population from the start, however, I would argue targeting non-hospitalized patients was a larger market that could benefit from oral therapy. Indeed, I would like to see the company go after the hospital setting, but I am not sure the company can afford to run the trial without extensive dilution. Even if the company was to get funding and run another trial, I doubt the future COVID-19 market will be worth the dilution. As a result, I have to brand Tempol's COVID-19 adventure as another failure at this point in time. Nevertheless, I am still hopeful the company can gather enough data to get Tempol approved for a broad label that deals with ARDS or an anti-inflammatory indication. Adamis Pharmaceuticals Pipeline (Adamis Pharmaceuticals) No Hope? Admittedly, my recap of failures might be incredibly discouraging to current and future ADMP investors. However, I will point out that there is some hope for Adamis and its shareholders. First of all, Tempol has potential, so there is some value left in the asset. I believe we could see Tempol used in other COVID-19 indications. In addition, Tempol should be operative in other respiratory illnesses. In addition, Adamis has Symjepi and Zimhi left in the portfolio that could deliver significant revenue in the coming years. Zimhi is the company's high-dose naloxone rescue device for opioid overdoses, which is supposed to be the company's second chance after Symjepi's dud of a launch. However, Zimhi also had a rough road to approval with fights off reference drug issues and a CRL. US WorldMeds should have better luck with Zimhi considering they have a complementary product in their portfolio and the U.S. government is allocating $1.5B to fight the opioid epidemic and increase access to naloxone. But, US WorldMeds is going to have to make some deals rather than hope organizations decide to stumble upon their Zimhi direct ordering website. There is a huge opportunity for Zimhi to be a major player in the opioid epidemic and potentially turn this ship around... but there is a possibility that Zimhi will go the way of Symjepi.
Seeking Alpha • Jul 29

Next meeting of data safety board to review Adamis Pharma's COVID treatment in Sept.

Adamis Pharmaceuticals (NASDAQ:ADMP) on Friday said the next meeting of a data safety board to review interim results from the company's ongoing phase 2/3 trial of its potential COVID-19 treatment had been set for late Sept. ADMP in the mid-to-late stage trial is evaluating the safety and efficacy of its nitroxide Tempol in COVID patients early in the infection. The Data Safety Monitoring Board (DSMB) had previously met to analyze interim data from the trial in March and June, and both times had recommended that the study continue without any changes. “With more than 200 patients enrolled, we believe this next DSMB data review could provide important additional insights into the safety and treatment effects of Tempol, as well as the future clinical path for Tempol,” said ADMP CEO David Marguglio. Adamis (ADMP) stock +1% to $0.37 in early trading.
Seeking Alpha • Jul 21

Adamis CEO urges stock split approval, slate of directors in letter to shareholders

Adamis Pharmaceuticals (NASDAQ:ADMP) CEO David Marguglio has penned a letter to shareholders urging them to vote in favor of several proposals at its August annual meeting, including authorizing a potential reverse stock split. In Thursday morning trading, shares are currently $0.44, down 10%. The reverse stock split would allow shares to trade above $1, meeting a Nasdaq requirement. "With the present 15 million authorized shares of common stock currently available for future issuance, it is unlikely that we will be able to execute any significant future transactions," Marguglio noted. Marguglio also urged shareholders to vote for the slate of five board directors, noting that the number of independent directors was changed recently to four from three "reducing management influence and increasing Board independence and diversity." The exec also ask shareholders to approve a proposal that would adjourn the meeting if there is an insufficent number of votes to effect the reverse stock split proposal. Adamis (ADMP) are down 29% year to date. Marguglio, one of the company's cofounders, just became CEO in May.
Seeking Alpha • Apr 13

Adamis Pharmaceuticals: Preparing For Another Round Of Success, Failure, Then Hope

Adamis Pharmaceuticals has two intramuscular injection rescue products approved by the FDA, SYMJEPI, and ZIMHI. In addition, the company's COVID-19 candidate, TEMPOL, has shown incredible promise thus far. Despite hitting their objectives and making significant progress, these efforts didn’t move the needle in the positive direction for earnings and the share price. The company has a history of making progress but they fail to capitalize on that progress. Yet, they still find another opportunity to be a source of hope for investors. I am going to hold off on accumulating more shares at these levels and will switch to a discounted valuation to determine my buy target. I reveal my new buy target. I am still looking to hold my ADMP shares and the ticker will remain in Compounding Healthcare’s Bio Boom Portfolio for the foreseeable future.
Seeking Alpha • Jan 20

Adamis Pharmaceuticals: Market Continues To Overlook TEMPOL's Potential To Be A Leading COVID-19 Therapeutic

Adamis Pharmaceuticals is moving TEMPOL forward against COVID-19. The FDA recently announced that they submitted a Fast Track application for TEMPOL. TEMPOL has the potential to both prevent disease progression and reduce replication. I match TEMPOL up against contemporary COVID-19 products. TEMPOL has numerous attributes that could make it a leading product for COVID-19. I discuss some of the mechanisms that allow TEMPOL to work against COVID-19. Despite my views on TEMPOL's potential, I am still cautiously optimistic about the company's ability to handle TEMPOL from start to finish. I reveal my plans for my ADMP position as we wait for TEMPOL's Phase II/III COVID-19 trial to conclude.
Seeking Alpha • Dec 02

Adamis Pharmaceuticals: It's Now Or Never

Adamis Pharmaceuticals has two FDA-approved products and a potential blockbuster drug in TEMPOL. However, the company has a long history of blunders that have devastated the share price. I believe the company has a chance to make 2022 a turnaround year, but it is going to require making deals and not excuses to get investors reinvigorated about ADMP. I discuss some of the leading downside risks that investors should be aware of. Finally, I reveal my plan for trading ADMP through the rest of 2021 and throughout 2022.
Seeking Alpha • Sep 03

Adamis Pharmaceuticals: TEMPOL's Near-Term And Long-Term Upside Improves As Variants Sidestep Vaccines

Despite vaccines having some degree of efficacy against SARS-CoV-2, vaccinated patients around the world are still getting infected and capitulating to COVID-19. Antiviral drugs could be the answer. Adamis Pharmaceuticals has an antiviral candidate, TEMPOL, which has the prospects to be operative at several stages of the infection. TEMPOL is not the only antiviral drug in development, however, it has unique characteristics that could make it a leading product that may secure huge government contracts. I reveal my updated strategy for accumulating ADMP ahead of ZIMHI PDUFA date and TEMPOL catalysts.

Aktionärsrenditen

DMKP.QUS PharmaceuticalsUS Markt
7D0%1.9%-0.8%
1Y-100.0%41.8%27.1%

Rendite im Vergleich zur Industrie: DMKP.Q unter dem Niveau der Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 41.8% erzielte.

Rendite vs. Markt: DMKP.Q hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 27.1 erzielte.

Preisvolatilität

Is DMKP.Q's price volatile compared to industry and market?
DMKP.Q volatility
DMKP.Q Average Weekly Movement466,513.1%
Pharmaceuticals Industry Average Movement10.0%
Market Average Movement7.2%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.2%

Stabiler Aktienkurs: Der Aktienkurs von DMKP.Q war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.

Volatilität im Zeitverlauf: DMKP.QDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 198704% auf 466513% gestiegen.

Über das Unternehmen

GegründetMitarbeiterCEOWebsite
n/a12Eddie Gloverwww.dmkpharmaceuticals.com

DMK Pharmaceuticals Corporation, ein Neurobiotechnologie-Unternehmen in der klinischen Phase, entwickelt und vermarktet Produkte in den therapeutischen Bereichen Allergie, Opioidüberdosierung, Atemwegs- und Entzündungskrankheiten. Der führende Produktkandidat des Unternehmens in der klinischen Phase, DPI-125, ist für die Behandlung von Opioidkonsumstörungen geeignet. Zu den Produkten des Unternehmens gehören SYMJEPI, eine Epinephrin-Injektion für die Notfallbehandlung von allergischen Reaktionen auf stechende und beißende Insekten, Allergen-Immuntherapie, Nahrungsmittel, Medikamente, diagnostische Testsubstanzen und andere Allergene sowie idiopathische oder trainingsinduzierte Anaphylaxie, und ZIMHI, eine Naloxon-Injektion für die Behandlung von Opioid-Überdosierungen.

DMK Pharmaceuticals Corporation's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von DMK Pharmaceuticals im Vergleich zum Marktanteil des Unternehmens?
DMKP.Q grundlegende Statistiken
MarktanteilUS$10.00
Gewinn(TTM)-US$21.33m
Umsatz(TTM)US$3.62m
0.0x
Kurs-Umsatz-Verhältnis
0.0x
Kurs-Gewinn-Verhältnis

Ist DMKP.Q zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
DMKP.Q Gewinn- und Verlustrechnung (TTM)
EinnahmenUS$3.62m
Kosten der EinnahmenUS$4.97m
Bruttogewinn-US$1.35m
Sonstige AusgabenUS$19.98m
Gewinn-US$21.33m

Zuletzt gemeldete Gewinne

Sep 30, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)-2.11
Bruttomarge-37.30%
Nettogewinnspanne-589.28%
Schulden/Eigenkapital-Verhältnis0%

Wie hat sich DMKP.Q auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2024/11/21 23:27
Aktienkurs zum Tagesende2024/11/19 00:00
Gewinne2023/09/30
Jährliche Einnahmen2022/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

DMK Pharmaceuticals Corporation wird von 5 Analysten beobachtet. 0 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Andrew D'SilvaB. Riley Securities, Inc.
Jason KolbertH.C. Wainwright & Co.
Jason KolbertMaxim Group